RegenXBio (RGNX) AI Stock Analysis

• Market Cap: $440.40M
• Dividend Yield: N/A
• Average Volume (3M): 1.07M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.12
• Revenue Growth: 80.70%
• EPS Growth: 46.66%
• Country: US
• Employees: 353
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): 0.12
• Shares Outstanding: 50,388,695
• 10 Day Avg. Volume: 1,000,266
• 30 Day Avg. Volume: 1,071,483
• PEG Ratio: 0.01
• Price to Book (P/B): 1.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.11
• Enterprise Value/Market Cap: 2.22
• Enterprise Value/Revenue: 2.36
• Enterprise Value/Gross Profit: 8.14
• Enterprise Value/Ebitda: -1.28
• 1Y Price Target: $32.00
• Price Target Upside: 266.13% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 52 Neutral
• Price Target: $8.50 ▼(-2.75%Downside)

RegenXBio's overall stock score reflects significant financial challenges and valuation concerns, tempered by positive developments in their clinical pipeline and strategic partnerships. The recent royalty monetization deal provides a financial boost, but regulatory and competitive pressures remain key risks.

Positive Factors

Clinical Trial Enrollment

Enrollment in the pivotal portion of AFFINITY DUCHENNE has surpassed 50%, indicating strong interest in the trial.

Regulatory Interactions

Interactions with regulatory agency have been positive, with accelerated approval still remaining on the table.

Safety Profile

RGX-202 has a clean safety profile with no serious adverse events reported in the 13 patients treated thus far.

Negative Factors

Concerns on Safety

A second acute liver failure-related death in a non-ambulatory DMD patient infused with Elevidys raises concerns in the context of similar therapies.

Gene Therapy Sentiment

Recent events are expected to weigh on sentiment for gene therapy stocks across the S&P 600 Health Care Index.

RegenXBio Business Overview & Revenue Model

Company Description

RegenXBio Inc. is a biotechnology company specializing in the development, commercialization, and licensing of gene therapy products. It operates in the biopharmaceutical sector with a focus on leveraging its proprietary NAV Technology Platform to develop transformative treatments for retinal, neurodegenerative, and metabolic diseases. RegenXBio's core products and services include a pipeline of internally developed gene therapy candidates and partnerships with other biopharmaceutical companies to advance novel therapeutic solutions.

How the Company Makes Money

RegenXBio makes money through a combination of product development, licensing agreements, and strategic partnerships. A significant portion of the company's revenue is derived from licensing its NAV Technology Platform to other biotech and pharmaceutical companies, allowing them to develop their own gene therapy products. These licensing agreements often include upfront payments, milestone payments based on the achievement of specific development or regulatory goals, and royalties on future sales of licensed products. Additionally, RegenXBio generates revenue through collaborations and partnerships that involve co-development or co-commercialization of therapeutic candidates, sharing both the risks and potential rewards of product development. The company's revenue model is heavily dependent on the success of its gene therapy candidates, both those developed internally and those advanced through partnerships.

RegenXBio Financial Statement Overview

Summary

RegenXBio faces significant financial challenges with ongoing net losses despite healthy gross profit margins. The balance sheet shows moderate strength with manageable debt levels, but the negative net profit margin and cash flow issues remain concerning. Improvement in free cash flow is a positive sign, yet profitability is needed to leverage equity effectively.

Income Statement

RegenXBio's income statement shows significant challenges with profitability. The company's gross profit margin is healthy at approximately 76.55% TTM, but it is overshadowed by persistent net losses, as indicated by a negative net profit margin of -100.62% TTM. Revenue growth shows volatility, with a recent increase of 88.04% from the previous year, yet this is not translating into profits. EBIT and EBITDA margins are also negative, reflecting ongoing operational losses.

Balance Sheet

The balance sheet reveals a moderate financial position with a debt-to-equity ratio of 0.29 TTM, indicating a manageable debt level relative to equity. The equity ratio is 55.84% TTM, suggesting a decent proportion of assets financed by equity. However, the company's return on equity remains negative due to sustained net losses, highlighting the need for improved profitability to leverage equity effectively.

Cash Flow

RegenXBio's cash flow statement presents a mixed picture. Operating cash flow is negative, reflecting cash burn from operations. Despite this, the free cash flow has shown improvement, with a reduction in negative free cash flow by 50.47% from the previous year. The ratio of operating cash flow to net income is above 1, indicating that the company is effective in converting net income (albeit negative) into operating cash flow, yet free cash flow remains a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	156.72M	83.33M	90.24M	112.72M	470.35M	154.57M
Gross Profit	119.95M	49.76M	53.03M	58.18M	418.51M	118.85M
EBITDA	-128.92M	-198.23M	-239.46M	-244.24M	169.54M	-96.83M
Net Income	-157.69M	-227.10M	-263.49M	-280.32M	127.84M	-111.25M
Balance Sheet
Total Assets	490.93M	465.99M	573.97M	833.27M	1.11B	708.16M
Cash, Cash Equivalents and Short-Term Investments	267.87M	234.69M	275.26M	364.64M	457.44M	475.74M
Total Debt	79.85M	82.03M	89.29M	94.80M	86.68M	72.65M
Total Liabilities	216.73M	206.34M	262.23M	317.07M	349.61M	330.41M
Stockholders Equity	274.20M	259.65M	311.74M	516.20M	764.30M	377.75M
Cash Flow
Free Cash Flow	-86.94M	-175.56M	-228.37M	-238.21M	134.70M	-80.93M
Operating Cash Flow	-84.04M	-173.13M	-218.41M	-207.49M	218.88M	-54.06M
Investing Cash Flow	135.01M	103.45M	190.94M	-11.93M	-406.64M	122.76M
Financing Cash Flow	-33.84M	92.68M	-34.97M	-28.84M	195.25M	200.21M

RegenXBio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.74
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGNX, the sentiment is Positive. The current price of 8.74 is below the 20-day moving average (MA) of 8.89, below the 50-day MA of 9.00, and above the 200-day MA of 8.60, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 49.53 is Neutral, neither overbought nor oversold. The STOCH value of 60.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RGNX.

RegenXBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMLX	58 Neutral	$585.66M	―	-83.24%	―	-100.32%	-197.69%
TSHA	54 Neutral	$635.52M	―	-159.34%	―	-48.97%	69.32%
RGNX	52 Neutral	$440.40M	―	-47.44%	―	80.70%	46.66%
VERV	52 Neutral	$999.30M	―	-34.26%	―	271.44%	26.65%
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
IVA	45 Neutral	$434.63M	―	344.74%	―	-47.32%	-26.67%
ERAS	34 Underperform	$407.93M	―	-45.82%	―	―	10.38%

RegenXBio Corporate Events

RegenXBio Holds 2025 Annual Stockholders Meeting

At REGENXBIO Inc.’s 2025 Annual Meeting of Stockholders held on May 30, 2025, several key proposals were voted on. Four individuals were elected as Class I directors to serve until 2028, and PricewaterhouseCoopers LLP was ratified as the independent public accounting firm for the year. Additionally, stockholders approved the executive compensation plan and decided to hold annual advisory votes on this matter. The 2025 Equity Incentive Plan was also approved.

The most recent analyst rating on (RGNX) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on RegenXBio stock, see the RGNX Stock Forecast page.

RegenXBio Secures $250M Royalty Monetization Deal

On May 16, 2025, REGENXBIO Inc. announced a strategic royalty monetization agreement with HealthCare Royalty Management, LLC, securing up to $250 million in non-dilutive funding through a limited recourse royalty bond. This agreement provides immediate capital of $150 million, extending the company’s cash runway into early 2027 and supporting its late-stage gene therapy programs. The deal allows REGENXBIO to leverage anticipated royalties from products like ZOLGENSMA® and potential future milestones, positioning the company to accelerate commercial preparations and maintain its leadership in gene therapy.

The most recent analyst rating on (RGNX) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on RegenXBio stock, see the RGNX Stock Forecast page.